None

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) inves...

CEL-SCI receives Japanese patent for investigational Phase 3 cancer therapy

The Japanese patent office has issued a patent covering CEL-SCI Corporation’s investigational cancer drug, Multikine, titled, ‘A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation...

Multikine: Phase III ongoing

Cel-Sci's Successful Safety Review Not Yet Factored Into Valuation

By Ray Dirks:CEL-SCI Corp. (AMEX: CVM) released news last week that pretty much went unnoticed by investors during a very rough negative trending market, this judging by the non-reaction of the compan...

Cel-Sci: Immunotherapy Opens New Door To Investors

By James Stocklasar Thomas Jr.:In my last article about a well-known pharmaceutical giant, I observed that : Teva Pharmaceuticals (TEVA) is one of the behemoths in the pharmaceutical industry with a...

CEL-SCI Corporation Releases New Video on Its Website

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has released a new video about its investigational cancer drug Multikine* and the dedicated manufacturing facility to p...

CEL-SCI Receives Key Japanese Patent for Its Investigational Phase III Cancer Therapy Multikine

CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Japanese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine (Leukocyte...

None